Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406479 | 0.83 | LMNA (0.71) | HPGDLMNARAB9AKMT2AL3MBTL1 | |
| SCHEMBL12125388 | 0.81 | HPGD (0.67) | HPGDNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL16192946 | 0.81 | NPC1 (0.58) | NPC1RAB9AKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL26417587 | 0.80 | HPGD (0.65) | HPGDLMNANPC1RAB9AKMT2A | |
| SCHEMBL16192934 | 0.76 | TSHR (0.51) | HPGDLMNANPC1RAB9AKMT2A | |
| SCHEMBL14995962 | 0.76 | HPGD (0.73) | HPGDLMNANPC1RAB9AKMT2A | |
| SCHEMBL20665546 | 0.76 | HPGD (0.73) | HPGDLMNA | |
| SCHEMBL15562668 | 0.74 | HPGD (1.00) | HPGDLMNARAB9AKMT2AALDH1A1 | |
| SCHEMBL24431446 | 0.74 | HPGD (0.65) | HPGDLMNANPC1RAB9AALDH1A1 | |
| SCHEMBL17637645 | 0.74 | MAPK14 (0.56) | HPGDLMNANPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160090351-A1 | INHIBITORS OF DEUBIQUITINATING PROTEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-31 | — | — | US | disclosed |
| US-20160090351-A1 | INHIBITORS OF DEUBIQUITINATING PROTEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090351-A1 | INHIBITORS OF DEUBIQUITINATING PROTEASES | USP1, USP2, USP18 | HPGD 2932/4885LMNA 4033/4885NPC1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.